rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACTU
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Wednesday's After-Market Session
      7h agoBenzingaACTUSLXN
      Actuate Therapeutics Reports Positive Monotherapy Data in Aggressive Melanoma Preclinical Model with Daily Dosing of Elraglusib Oral Tablet at ENA 2026

      Daily oral elraglusib achieved up to 77% tumor growth inhibition as monotherapy in an aggressive preclinical melanoma model, with greater antitumor activity observed at higher drug exposuresTreatment was associated with changes in the tumor immune microenvironment, characterized by increased cytotoxic T cells and natural killer cells and reduced immunosuppressive myeloid cellsFindings further reinforce initiation of Phase 1/2 clinical trial in Q1 2027 with daily dosing of elraglusib oral tablet

      15h agoYahoo FinanceACTU
      Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026

      - Oral tablet formulation of elraglusib as a monotherapy significantly inhibited tumor growth and enhanced antitumor immune activity in an aggressive, poorly immunogenic melanoma model - Phase 1/2 clinical trial evaluating Elraglusib Oral Tablet to be initiated in Q1 2027 CHICAGO and FORT WORTH, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatm

      Nov 4Yahoo FinanceACTU
      Actuate Therapeutics CEO Daniel Schmitt purchases $49,999 in stock
      Nov 1Investing.comACTU
      Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering
      Oct 27Yahoo FinanceACTU
      12 Health Care Stocks Moving In Friday's Intraday Session - Marker Therapeutics (NASDAQ:MRKR), Alaunos Th
      Oct 16BenzingaACTUMRKRTCRT
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session
      Oct 7BenzingaACTULPCNSXTC
      12 Health Care Stocks Moving In Tuesday's After-Market Session - China SXT Pharmaceuticals (NASDAQ:SXTC)
      Oct 6BenzingaACTUSBFMSBFMWSXTC
      12 Health Care Stocks Moving In Monday's After-Market Session
      Sep 28BenzingaACTUCMMBSLXN
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Sep 25BenzingaACTU
      Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

      Independent studies conducted at Northwestern University and Mayo Clinic demonstrate synergistic activity of elraglusib in combination with RAS-targeted agents across multiple murine and human pancreatic cancer modelsData further support the potential for combination therapy strategies across other RAS-driven cancers Additional studies are ongoing with results to be presented at upcoming medical conferences CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, I

      Sep 9Yahoo FinanceACTU
      Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one mee

      Sep 9Yahoo FinanceACTU
      All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

      Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Sep 2Yahoo FinanceACTUINTS

      This is the newest page. Registered accounts read further back.